Frankfurt Am Main

• A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended
  2022-500332-11-00 4 2022-11-25 systemic sclerosis
• Phase I study of MGY825 in patients with lung cancer Ended
  2023-504350-36-00 1 2022-11-25 Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• Caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombo … Ended
  2024-513262-19-00 5 2022-11-21 Thrombotic Thrombocytopenic Purpura
• Safety and Immunogenicity of V116 in Adults 50 Years of Age or Older Ended
  2022-503144-40-00 5 2022-11-17 Pneumococcal disease
• A long-term study to evaluate if KVD900 is safe and effective in treating attacks in patients with Hereditary Angioedema. Ended
  2023-505904-41-00 5 2022-11-17 Hereditary Angioedema Type I or II
• Safety and efficacy of PC945 (opelconazole) in combination with other antifungal therapy for the treatment of refractory invasive pulmonary … Ended
  2024-511281-36-00 5 2022-11-17 Refractory Invasive Pulmonary Aspergillosis
• PEARLDIFER - A Phase II study of pemigatinib after curative local therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harbori … Ended
  2024-512018-16-00 4 2022-11-11 locally advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fus
• Trial investigating a personalized treatment, based on age and tumor characteristics , of newly diagnosed medullablastoma in patients that a … Ended
  2023-506193-12-00 4 2022-11-10 Newly Diagnosed Medulloblastoma
• Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia Ended
  2023-507748-35-00 1 2022-11-08 Acute Myeloid Leukemia
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
• Early Reperfusion Therapy for Recovery of Vision in Acute Central Retinal Artery Occlusion Ended
  2023-507388-21-00 5 2022-09-08 Acute non-arteritic central retinal artery occlusion (CRAO)
• Phase 1/2 study of Nivolumab and Relatlimab in Combination with Bevacizumab in First-line HCC Ended
  2024-510649-33-00 9 2022-09-02 Advanced/metastatic hepatocellular carcinoma (HCC)
• A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Ended
  2024-510729-24-00 6 2022-09-01 Chronic Migrane, Migrane, Medication Overuse Headache
• A multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the rate of weekly lipoprotein apheresis ses … Ended
  2023-508324-35-00 5 2022-08-19 Apheresis
• A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorect … Ended
  2023-503797-21-00 5 2022-08-10 Metastatic Colorectal Cancer
• A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or … Ended
  2023-504257-12-00 4 2022-07-28 Portal hypertension
• Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) th … Ended
  2024-515485-14-00 5 2022-07-07 Acute major bleeding in patients receiving DOAC therapy with factor Xa
• A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination … Ended
  2024-511352-41-00 3 2022-06-13 advanced solid tumors
• A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alon … Ended
  2023-506981-30-00 4 2022-05-25 Chronic kidney disease in type 2 diabetes mellitus
• ADJUBIL - A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJ … Ended
  2024-511847-24-00 4 2022-05-23 Biliary tract cancer
• RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Ended
  2023-505441-69-00 5 2022-05-17 refractory, advanced gastro-oesophageal cancer
• A blinded, placebo-controlled and randomized phase 2 study to test different doses of oral PHA-022121 for prophylaxis of angioedema attacks … Ended
  2023-505549-18-00 4 2022-04-29 Hereditary angioedema due to C1-Inhibitor Deficiency (Type I or Type I
• "A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJ … Ended
  2023-506278-10-00 5 2022-04-22 Eosinophilic esophagitis

Showing 817–840 of 912 trials